Current knowledge and future research directions in treatment-related second primary malignancies

Publication date: June 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 1 Author(s): Lindsay M. Morton , Anthony J. Swerdlow , Michael Schaapveld , Safaa Ramadan , David C. Hodgson , John Radford , Flora E. van Leeuwen Currently, 17–19% of all new primary malignancies occur in survivors of cancer, causing substantial morbidity and mortality. Research has shown that cancer treatments are important contributors to second malignant neoplasm (SMN) risk. In this paper we summarise current knowledge with regard to treatment-related SMNs and provide recommendations for future research. We address the risks associated with radiotherapy and systemic treatments, modifying factors of treatment-related risks (genetic susceptibility, lifestyle) and the potential benefits of screening and interventions. Research priorities were identified during a workshop at the 2014 Cancer Survivorship Summit organised by the European Organisation for Research and Treatment of Cancer. Recently, both systemic cancer treatments and radiotherapy approaches have evolved rapidly, with the carcinogenic potential of new treatments being unknown. Also, little knowledge is available about modifying factors of treatment-associated risk, such as genetic variants and lifestyle. Therefore, large prospective studies with biobanking, high quality treatment data (radiation dose–volume, cumulative drug doses), and data on other cancer risk factors are needed. International collaboration...
Source: European Journal of Cancer Supplements - Category: Cancer & Oncology Source Type: research